Gleevac, also called imatinib mesylate, is approved by the FDA to treat some types of leukemia and other forms of cancer.
What does IM stand for?
IM stands for Imatinib Mesylate (oncology)
This definition appears very rarely and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of IM
We have 59 other meanings of IM in our Acronym Attic
- I Love You With All My Heart And Soul
- Zilina D. Hricov, Slovak Republic (airport code)
- India Lead Zinc Development Association
- International Lead Zinc Research Organization
- International Lead and Zinc Study Group
- Ice Maker
- Ideas in Movement (San Marino)
- Identity Management (information security)
- IMAC (Apple Computer)
- Image (mathematics)
Samples in periodicals archive:
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRApositive chronic eosinophilic leukemia: implications for optimal dosing.
Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
Imatinib mesylate, an inhibitor of Bcr-Abl tyrosine kinases, has revolutionized the treatment of chronic myelogenous leukemia (CML), showing marked improvements in survival in all three phases of the disease: chronic, accelerated, and blast crisis (see Figure 1).
The first in this class was imatinib mesylate (Gleevec), which occupies the ATP binding site of the tyrosine kinase, and prevents subsequent phosphorylation of tyrosine residues on affected proteins.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec A[R]) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
The positive opinion was also granted for gastrointestinal stromal tumor (GIST), a rare stomach and intestinal cancer, in patients who are resistant or intolerant to imatinib mesylate.
Coverage includes techniques for the detection of BCR-ABL mutations and resistance to imatinib mesylate, detection of the FIP 1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia, classification of acute myeloid leukemia by DNA- oligonucleotide microarrays, detection of the V617F JAK2 mutation in myeloproliferative disorders, gene rearrangements, FLT3 mutations andWT-1 overexpression.